Journal article

Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat)

Lei Zhang, David Lebwohl, Eric Masson, Glen Laird, Michael R Cooper, H Miles Prince

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2008

DOI: 10.1200/JCO.2007.14.7249

Citation metrics

34Web of Science
38Scopus
36Dimensions

Keywords

Science & Technology
Depsipeptide
T-Cell Lymphoma
Hematologic Malignancies
Suberoylanilide Hydroxamic Acid
Phase-I
Hematologic Neoplasms
Hydroxamic Acids
Indoles
Long Qt Syndrome
Panobinostat
Humans
Oncology
Trial
Life Sciences & Biomedicine
Histone Deacetylase Inhibitor
Vorinostat
Dose-Response Relationship, Drug